You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(688180.SH):JS001sc注射液的臨牀試驗申請獲得受理
格隆匯 12-23 17:05

格隆匯12月23日丨君實生物(688180.SH)公佈,近日,公司收到國家藥品監督管理局核准簽發的《受理通知書》JS001sc 注射液(項目代號JS001sc)的臨牀試驗申請獲得受理。

JS001sc注射液是公司在已上市產品特瑞普利單抗注射液(商品名:拓益®產品代號:JS001)的基礎上開發的皮下注射製劑。JS001sc以人PD-1為靶點高親和力結合PD-1,選擇性阻斷PD-1配體PD-L1PD-L2的結合,從而活 T 淋巴細胞,提高淋巴細胞的增殖及細胞因子的分泌。臨牀前體內藥效試驗明,JS001sc通過皮下注射給藥在動物模型中表現顯著的抑瘤作用0.3mg/kg的劑量水平,皮下注射給藥JS001sc與靜脈注射給藥特瑞普利單抗抑瘤作用相當,未見顯著差異。此外,動物對 JS001sc 的耐受性良好

隨着腫瘤免疫治療“慢病化管理”的理念逐步普及,相比於頻繁前往醫院進行數小時的靜脈注射,短時間的皮下注射給藥具有更的吸引力。同時皮下注射可避免靜脈注射給藥方式造成的輸注相關不良反應,使患者整體獲益,並減少醫療成本經查詢公開信息,截至公吿披露日,全球範圍內已上市的十餘種PD-(L)1 抗體中,恩沃利單抗注射液(商品名:恩維達®)為皮下注射給藥產品均為靜脈注射給藥

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account